Entheon Biomedical Corp. operates as a biotechnology research and development company. The firm engages in developing and commercializing dimethyltryptamine based psychedelic therapeutic products. Its therapies aim to treat addiction and substance use disorders. The company was founded on April 6, 2010 and is headquartered in Vancouver, Canada.